Drug intelligence / Profile preview

Oro-210

Development stage: Preclinical
Lead developer: OroGen BioSciences
Modality: Small Molecules
Administration: Oral

Overview

Oro-210 is a small molecule dual inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) under development by OroGen Therapeutics (also referred to as OroGen BioSciences). The drug is currently in the IND-enabling (preclinical) stage of development for the treatment of autoimmune diseases.

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on Oro-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oro-210.

Explore the full profile